Abstract
A number of studies have identified differential kavalactone activity against a variety of molecular targets, including P glycoprotein (Pgp), platelet monoamine oxidase (MAO-B), transcription factor binding domains, pregnane X (PXR) and GABA receptors, and cytochrome P450 and cyclo-oxygenase (COX) enzymes. The molecular structure of the kavalactones possesses a pharmacophore for several of these targets. In most cases, conformational stability is more significant than the substituents present. The analysis of these pharmacophores provides important insights for future medicinal chemistry-based approaches to kavalactone-type drugs.
Keywords: Kavalactone, pharmacophore, molecular targets, conformational isomerism, Piper methysticum, P-Glycoprotein (Pgp), kavain/dihydrokavain, methysticin/dihydromethysticin, desmethoxyyangonin, Cyclo-Oxygenase Enzymes, COX, NSAIDs, luciferase-based assay, Kavain, 7,8-Dihydrokavain, Methysticin, 7,8-Dihydromethysticin, Yangonin, Cytochrome P450, Pregnane X Receptor, GABA, LITAF
Mini-Reviews in Medicinal Chemistry
Title: Kavalactone Pharmacophores for Major Cellular Drug Targets
Volume: 11 Issue: 1
Author(s): A. Rowe, R. Narlawar, P. W. Groundwater and I. Ramzan
Affiliation:
Keywords: Kavalactone, pharmacophore, molecular targets, conformational isomerism, Piper methysticum, P-Glycoprotein (Pgp), kavain/dihydrokavain, methysticin/dihydromethysticin, desmethoxyyangonin, Cyclo-Oxygenase Enzymes, COX, NSAIDs, luciferase-based assay, Kavain, 7,8-Dihydrokavain, Methysticin, 7,8-Dihydromethysticin, Yangonin, Cytochrome P450, Pregnane X Receptor, GABA, LITAF
Abstract: A number of studies have identified differential kavalactone activity against a variety of molecular targets, including P glycoprotein (Pgp), platelet monoamine oxidase (MAO-B), transcription factor binding domains, pregnane X (PXR) and GABA receptors, and cytochrome P450 and cyclo-oxygenase (COX) enzymes. The molecular structure of the kavalactones possesses a pharmacophore for several of these targets. In most cases, conformational stability is more significant than the substituents present. The analysis of these pharmacophores provides important insights for future medicinal chemistry-based approaches to kavalactone-type drugs.
Export Options
About this article
Cite this article as:
Rowe A., Narlawar R., W. Groundwater P. and Ramzan I., Kavalactone Pharmacophores for Major Cellular Drug Targets, Mini-Reviews in Medicinal Chemistry 2011; 11 (1) . https://dx.doi.org/10.2174/138955711793564088
| DOI https://dx.doi.org/10.2174/138955711793564088 |
Print ISSN 1389-5575 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Elevated Levels of Soluble Fibrin in Patients with Thrombosis or a Pre- Thrombotic State
Vascular Disease Prevention (Discontinued) Cholangiocarcinoma Therapeutics: An Update
Current Cancer Drug Targets Role of Cytokines in Regulating Feeding Behaviour
Current Drug Targets The Significance of Transferrin Receptors in Oncology: the Development of Functional Nano-based Drug Delivery Systems
Current Drug Delivery Current Status and Future of Target-Based Therapeutics
Current Cancer Drug Targets Plant Ribonucleases and Nucleases as Antiproliferative Agens Targeting Human Tumors Growing in Mice
Recent Patents on DNA & Gene Sequences CDK-associated Cullin 1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Human Glioblastoma
Current Cancer Drug Targets Editorial Review of 2012
Current Radiopharmaceuticals Current Status of the Non-nucleoside Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Type 1
Current Topics in Medicinal Chemistry Which Dose of Folic Acid Should Pregnant Diabetic Women Receive?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Nelarabine- A New Purine Analog in the Treatment of Hematologic Malignancies
Reviews on Recent Clinical Trials Chemokine Receptors as Targets for Cancer Therapy
Current Pharmaceutical Design Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews MUC Glycoproteins: Potential Biomarkers and Molecular Targets for Cancer Therapy
Current Cancer Drug Targets Fighting Tumor Cell Survival: Advances in the Design and Evaluation of Pim Inhibitors
Current Medicinal Chemistry MYC as Therapeutic Target for Embryonal Tumors: Potential and Challenges
Current Cancer Drug Targets Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia
Current Drug Therapy Modulation of Huntington’s Disease in Drosophila
CNS & Neurological Disorders - Drug Targets The Role of Major Histocompatibility Complex Polymorphisms in the Incidence and Outcome of Non-Hodgkin Lymphoma
Current Immunology Reviews (Discontinued) Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment
Current Pharmaceutical Design




